Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-8421 in advanced solid tumors
NCT06034860Phase 1Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- RNA-Targeting Small Molecules, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of mt-8421 in non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), melanoma and 8 more (4 arms), sponsored by Molecular Templates, Inc. Primary endpoints: Number of participants with Adverse Events, Recommended Phase 2 Dose and 1 more. Started Nov 2023; status: terminated.
02
Drugs
mt-8421
03
Conditions
non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)melanomarenal cell carcinoma (RCC)malignancy
Beyond the preview
Go deeper on NCT06034860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034860.